Compumedics (ASX:CMP) 1-Year Sharpe Ratio: -0.03 (As of Jul. 01, 2026)


ASX:CMP Compumedics Ltd ASX:CMP
62 GF Score
Price A$0.27
GF Value A$0.32
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Compumedics 1-Year Sharpe Ratio?

Compumedics ASX:CMP +5.88% 62 1-Year Sharpe Ratio is -0.03 as of Jul. 01, 2026. GuruFocus rates ASX:CMP with a GF Score™ of 62/100 and a GF Value™ of A$0.32 (Modestly Undervalued). The stock has 6 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-01), Compumedics's 1-Year Sharpe Ratio is -0.03.

Compumedics  (ASX:CMP) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Compumedics 1-Year Sharpe Ratio Related Terms

ASX:CMP vs ABT, SYK, MDT: 1-Year Sharpe Ratio Comparison

For the Medical Devices subindustry, Compumedics's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compumedics 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Compumedics's 1-Year Sharpe Ratio falls into.


ASX:CMP
62GF Score
Compumedics Ltd ASX:CMP
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compumedics 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.03 mean?
Compumedics (ASX:CMP) has a 1-Year Sharpe Ratio of -0.03 as of Jul. 01, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Compumedics and its competitors.
Is Compumedics' 1-Year Sharpe Ratio too high?
Compumedics' current 1-Year Sharpe Ratio is -0.03. Overall, Compumedics has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' 1-Year Sharpe Ratio compare to ABT and SYK?
Compumedics' 1-Year Sharpe Ratio of -0.03 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Compumedics and its competitors. Compumedics's current 1-Year Sharpe Ratio is -0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.32, compared to a current price of A$0.27 — trading 15.6% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.03. Compumedics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current 1-Year Sharpe Ratio is -0.03 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compumedics (ASX:CMP) Overvalued in 2026?

Based on GuruFocus' analysis, Compumedics stock appears to be undervalued. The current stock price of A$0.27 is trading 15.6% below its estimated GF Value™ of A$0.32. GuruFocus considers Compumedics to be Modestly Undervalued.

Key valuation signals for ASX:CMP:

  • 1-Year Sharpe Ratio: -0.03
  • GF Value™: A$0.32 vs. price of A$0.27 (15.6% below fair value)
  • GF Score™: 62/100 with 6 warning signs

No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compumedics Business Description

Address 30-40 Flockhart Street, Abbotsford, Melbourne, VIC, AUS, 3067
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
62GF Score

Get the complete analysis for ASX:CMP

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.27
Price
A$0.32
GF Value